{
    "nct_id": "NCT06380751",
    "official_title": "A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)",
    "inclusion_criteria": "* Adult females, pre/peri-menopausal and/or post-menopausal, and adult males\n* Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer\n* Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease\n* ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks\n* FFPE tumour tissue from each participant\n* Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with history of MDS/AML or with features suggestive of MDS/AML\n* Participants with any known predisposition to bleeding\n* Any history of persisting severe cytopenia\n* Any evidence of severe or uncontrolled systemic diseases or active uncontrolled infections\n* Refractory nausea and vomiting, chronic GI disease, inability to swallow the formulated product, or previous significant bowel resection\n* History of another primary malignancy\n* Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy excluding alopecia\n* Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease\n* Evidence of active and uncontrolled hepatitis B and/or hepatitis C\n* Evidence of active and uncontrolled HIV infection\n* Active tuberculosis infection\n* Cardiac criteria, including history of arrythmia and cardiovascular disease\n* Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study\n* Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment\n* Prior treatment with systemic anti-cancer therapy for locoregionally recurrent or metastatic disease is not permitted, apart from treatment with ET up to 28 days before randomisation\n* Prior treatment within 28 days with blood product support or growth factor support\n* Any systemic concurrent anti-cancer treatment\n* Concomitant use of the following types of medications or herbal supplements within 21 days or at least 5 half-lives of randomisation:\n\n  1. Strong and moderate CYP3A4 inducers/inhibitors\n  2. Sensitive CYP2B6 substrates\n  3. Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index, eg, warfarin (and other coumarin-derived vitamin K antagonist anticoagulants) and phenytoin.\n* Concomitant use of drugs that are known to prolong QT and have a known risk of TdP\n* Systemic use of atropine\n* The following exclusion criteria apply to treatments administered for early breast cancer:\n\n  1. Disease progression ≤ 84 days following the last dose of neo-adjuvant or adjuvant chemotherapy\n  2. Disease progression ≤ 1 year (365 days) from the last dose of treatment with a PARPi and/or platinum agent for early breast cancer\n  3. Disease progression ≤ 1 year (365 days) from the last dose with a CDK4/6i in the adjuvant setting\n  4. Disease progression ≤ 1 year (365 days) from the last dose of an oral SERD including camizestrant.",
    "miscellaneous_criteria": ""
}